Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks for Hip Surgery Analgesia

NCT07531030 | Not Yet Recruiting

• 1 other identifier: FMASU MD274/2025
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the efficacy of adding a Posterior Pericapsular Deep gluteal block to two other standard nerve blocks-the Pericapsular Nerve Group block and the Lateral Femoral Cutaneous Nerve block-for patients undergoing orthopedic hip surgery. While standard blocks target the front of the hip, many patients still feel pain in the back (posterior) of the joint. Researchers will compare two groups of patients to see if this triple-block combination provides better pain relief and reduces the need for rescue opioid medications in the 24 hours following surgery.

Conditions

Postoperative Pain; Hip Osteoarthritis; Hip Fractures

Keywords

Posterior Pericapsular Deep Gluteal Block; Pericapsular Nerve Group Block; Lateral Femoral Cutaneous Nerve Block; Ultrasound-Guided Regional Anesthesia; Multimodal Analgesia; Orthopedic Hip Surgery

Outcome Measures

Primary Outcomes (1)

• Evaluation of Postoperative analgesic effect through Numerical Rating Scale Pain Score.

  Evaluation of postoperative analgesic effect through the Numerical Rating Scale for both static and dynamic pain. Static pain is measured after the patient has rested in bed for 15 minutes. Dynamic pain is measured with the hip joint flexed to 45 degrees. The scale ranges from 0 (no pain) to 10 (worst possible pain).

  6, 12, and 24 hours postoperatively.

Secondary Outcomes (4)

• Quadriceps Femoris Muscle Strength.

  1 hour before patient movement.

• Total Rescue Analgesia Consumption.

  First 24 hours postoperatively.

• Length of Hospital Stay.

  Approximately 24-72 hours (up to hospital discharge).

• Occurrence of Postoperative Complications.

  First 24 hours postoperatively.

Study Arms (2)

Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks.

ACTIVE COMPARATOR

Patients receive ultrasound-guided Pericapsular Nerve Group block and Lateral Femoral Cutaneous Nerve block using 10-15 ml of 0.25% bupivacaine for each block.

Procedure: Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks.

Posterior Pericapsular Deep Gluteal, Pericapsular Nerve Group, Lateral Femoral Cutaneous Nerve Block

EXPERIMENTAL

Patients receive ultrasound-guided Pericapsular Nerve Group block, Lateral Femoral Cutaneous Nerve block, and Posterior Pericapsular Deep gluteal block using 10-15 ml of 0.25% bupivacaine for each block.

Procedure: Posterior Pericapsular Deep Gluteal, Pericapsular Nerve Group, and Lateral Femoral Cutaneous Nerve Blocks.

Interventions

Posterior Pericapsular Deep Gluteal, Pericapsular Nerve Group, and Lateral Femoral Cutaneous Nerve Blocks. PROCEDURE

Under ultrasound guidance, patients receive a Pericapsular Nerve Group block, a Lateral Femoral Cutaneous Nerve block, and a Posterior Pericapsular Deep gluteal block. For each of the three blocks, 10-15 ml of 0.25% bupivacaine is injected while observing for adequate fluid spread over the respective anatomical targets.

Posterior Pericapsular Deep Gluteal, Pericapsular Nerve Group, Lateral Femoral Cutaneous Nerve Block

Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks. PROCEDURE

Patients receive ultrasound-guided Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve blocks with 10-15 ml of 0.25% bupivacaine for each block.

Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blocks.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age greater than or equal to 18 years. Both genders included. American Society of Anesthesiologists (ASA) physical status classification I-III.
• Undergoing elective orthopedic hip surgery. Provision of written informed consent.

You may not qualify if:

• Patient refusal of procedure or participation. American Society of Anesthesiologists (ASA) physical status classification IV. Allergy to any of the drugs used in the study. Local skin infection at the injection site. Coagulation disorder. History of cardiac arrhythmia, seizures, or increased intracranial tension. Alcohol or drug abuse, or psychiatric disease. History of chronic pain.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, Abbasia, 11591, Egypt

Location

MeSH Terms

Conditions

Pain, Postoperative; Osteoarthritis, Hip; Hip Fractures

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms; Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Femoral Fractures; Fractures, Bone; Wounds and Injuries; Hip Injuries; Leg Injuries

Central Study Contacts

Merna H Hilal, MSc, MB Bch

CONTACT

+201142220555; Merna.hazem@med.asu.edu.eg

Hany M El Zahaby, MD

CONTACT

+201227463000; Hanyzahaby@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants are randomly assigned to one of two groups to receive different regional anesthesia block combinations for postoperative analgesia.

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: April 15, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: April 15, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)